- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07950059
Effects of Inulin-Based Prebiotics on Gut Microbiota After Rectal Cancer Surgery (PUMCH-1-YSY)
Effects of Inulin-Based Compound Prebiotics on Postoperative Gut Microbiota Dysbiosis in Patients With Rectal Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Postoperative gut microbiota dysbiosis is a common clinical concern in patients undergoing rectal cancer surgery and may contribute to gastrointestinal dysfunction and postoperative complications. Inulin-based compound prebiotics may help maintain intestinal microbial balance by promoting beneficial bacteria and modulating gut microbial composition. However, their efficacy and safety in preventing postoperative gut microbiota dysbiosis in patients with rectal cancer remain to be established.
This study is a multicenter, randomized, double-blind, placebo-controlled, three-arm clinical trial designed to evaluate the efficacy and safety of inulin-based compound prebiotics in preventing gut microbiota dysbiosis following radical rectal cancer surgery and to assess their effects on gut microbiota composition.
A total of 261 adult patients with histologically confirmed rectal adenocarcinoma undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma will be enrolled at three study centers. Eligible participants will be randomly assigned in a 1:1:1 ratio to one of three groups: (1) inulin-based compound prebiotics combined with probiotics, (2) probiotics combined with placebo, or (3) placebo alone. Study interventions will be administered from postoperative day 1 through day 5.
The primary outcome is the incidence of gut microbiota dysbiosis within five days after surgery. Secondary outcomes include changes in gut microbiota composition and diversity, inflammatory markers, and fecal short-chain fatty acid levels. Gut microbiota will be assessed using 16S rRNA gene sequencing and metagenomic sequencing. Safety will be evaluated through the monitoring and recording of adverse events throughout the intervention period.
This study aims to provide clinical evidence regarding the efficacy and safety of inulin-based compound prebiotics for preventing postoperative gut microbiota dysbiosis and their potential role in modulating intestinal microbial homeostasis in patients undergoing rectal cancer surgery.
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Guole Lin
- Telefonní číslo: 010-13001081483
- E-mail: linguole@126.com
Studijní místa
-
-
-
Beijing, Čína, 100730
- Peking Union Medical College Hospital
-
Kontakt:
- Danyang Zhu
- Telefonní číslo: 010-13466711222
- E-mail: 17710202092@163.com
-
Beijing, Čína, 100000
- Beijing Friendship Hospital, Capital Medical University
-
Kontakt:
- Hongwei Yao
- Telefonní číslo: 010-13611015609
- E-mail: yaohongwei@ccmu.edu.cn
-
Beijing, Čína, 100007
- Beijing Sixth Hospital
-
Kontakt:
- Yi An
- Telefonní číslo: 010-13621224452
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Adults aged 18 years or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 before surgery.
- Histologically confirmed rectal adenocarcinoma diagnosed by endoscopic biopsy, with the lower margin of the tumor located ≤12 cm from the anal verge.
- Undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma.
- Willing and able to provide written informed consent, understand and comply with study requirements and procedures, and not currently participating in another clinical study considered by the investigator to conflict with this study.
Exclusion Criteria:
- Known intolerance to inulin or prebiotics.
- History of severe irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).
- Presence of distant metastases, including liver or lung metastases.
- Severe intestinal obstruction, gastrointestinal perforation, gastrointestinal bleeding, or other conditions requiring emergency treatment.
- Undergoing open radical rectal cancer surgery or conversion from laparoscopic to open surgery.
- Use of antibiotics (excluding planned perioperative antibiotic prophylaxis), prebiotics, probiotics, synbiotic products, or immunosuppressive agents within one month before surgery.
- Severe cardiovascular, cerebrovascular, hepatic, renal, pulmonary, or hematopoietic system diseases.
- Pregnant or breastfeeding women.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for inclusion in the study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Inulin-Based Compound Prebiotics Plus Probiotics
Participants in this group will receive oral inulin-based compound prebiotics (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), combined with compound Lactobacillus enteric-coated capsules (0.66 g three times daily) and a triple viable Bifidobacterium preparation (0.42 g three times daily). All interventions will be administered from postoperative day 1 through day 5. |
An oral inulin-based compound prebiotic supplement containing inulin (62.5%), polydextrose (10%), allulose (10%), isomaltooligosaccharides (7.88%), tagatose (7.75%), hyaluronic acid (1.25%), and chitosan oligosaccharides (0.63%). Participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g orally twice daily on postoperative days 2-5. The intervention will be administered in combination with probiotic preparations in the experimental group. An oral probiotic preparation containing two strains of Lactobacillus rhamnosus and Enterococcus faecium. Participants will receive 0.66 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group. An oral probiotic preparation containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Participants will receive 0.42 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group. |
|
Aktivní komparátor: Probiotics Plus Placebo
Participants in this group will receive compound Lactobacillus enteric-coated capsules (0.66 g orally three times daily) and a triple viable Bifidobacterium preparation (0.42 g orally three times daily), combined with maltodextrin placebo administered at the same dosage and schedule as the inulin-based compound prebiotics group. All interventions will be administered from postoperative day 1 through day 5. |
An oral probiotic preparation containing two strains of Lactobacillus rhamnosus and Enterococcus faecium. Participants will receive 0.66 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group. An oral probiotic preparation containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Participants will receive 0.42 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group. Maltodextrin will be used as a placebo to match the inulin-based compound prebiotic supplement and probiotic preparations. For the prebiotic-matched placebo, participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5. For the probiotic-matched placebo, participants will receive maltodextrin at doses of 0.66 g and 0.42 g, each administered orally three times daily from postoperative day 1 through day 5. The probiotics plus placebo group will receive the prebiotic-matched placebo, while the placebo comparator group will receive both placebo regimens. |
|
Komparátor placeba: Placebo
Participants in this group will receive oral maltodextrin placebo (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), together with additional maltodextrin placebo (0.66 g and 0.42 g, each administered orally three times daily) to match the probiotic preparations used in the other groups. All interventions will be administered from postoperative day 1 through day 5. |
Maltodextrin will be used as a placebo to match the inulin-based compound prebiotic supplement and probiotic preparations. For the prebiotic-matched placebo, participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5. For the probiotic-matched placebo, participants will receive maltodextrin at doses of 0.66 g and 0.42 g, each administered orally three times daily from postoperative day 1 through day 5. The probiotics plus placebo group will receive the prebiotic-matched placebo, while the placebo comparator group will receive both placebo regimens. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of Postoperative Gut Microbiota Dysbiosis
Časové okno: Postoperative days 1-5
|
The primary outcome is the proportion of participants who develop gut microbiota dysbiosis within five days following laparoscopic radical rectal cancer surgery with a protective intestinal stoma. Postoperative gut microbiota dysbiosis will be assessed based on clinical manifestations, including abdominal distension, diarrhea or increased stoma output, abdominal pain, fever, nausea, and vomiting, together with relevant laboratory findings. The incidence will be calculated as the number of participants diagnosed with postoperative gut microbiota dysbiosis divided by the total number of participants evaluated in each treatment group, expressed as a percentage. |
Postoperative days 1-5
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Changes in Gut Microbiota Composition and Diversity
Časové okno: Preoperatively and on postoperative days 3 and 5
|
Changes in gut microbiota composition and diversity will be assessed using metagenomic sequencing of fecal samples collected before surgery and during the postoperative period. Gut microbiota composition will be evaluated based on changes in microbial community structure and the relative abundance of bacterial taxa, while microbial diversity will be assessed using diversity indices derived from sequencing data. Changes in gut microbiota composition and diversity will be compared among the three treatment groups. |
Preoperatively and on postoperative days 3 and 5
|
|
Changes in the Bifidobacterium-to-Escherichia coli Ratio (B/E Ratio)
Časové okno: Preoperatively and on postoperative days 3 and 5
|
The Bifidobacterium-to-Escherichia coli ratio (B/E ratio) in fecal samples will be assessed using gut microbiota sequencing data. Changes in the B/E ratio will be compared among the three treatment groups to evaluate alterations in intestinal microbial balance following surgery. |
Preoperatively and on postoperative days 3 and 5
|
|
Serum C-Reactive Protein (CRP) Level
Časové okno: Preoperatively and on postoperative days 3 and 5
|
Serum C-reactive protein (CRP) levels will be measured to assess postoperative inflammatory responses. CRP concentrations will be compared among the three treatment groups. Results will be reported in mg/L. |
Preoperatively and on postoperative days 3 and 5
|
|
Serum Procalcitonin (PCT) Level
Časové okno: Preoperatively and on postoperative days 3 and 5
|
Serum procalcitonin (PCT) levels will be measured as an indicator of postoperative inflammatory responses. PCT concentrations will be compared among the three treatment groups. Results will be reported in ng/mL. |
Preoperatively and on postoperative days 3 and 5
|
|
Serum Interleukin-6 (IL-6) Level
Časové okno: Preoperatively and on postoperative days 3 and 5
|
Serum interleukin-6 (IL-6) levels will be measured to evaluate postoperative inflammatory responses. IL-6 concentrations will be compared among the three treatment groups. Results will be reported in pg/mL. |
Preoperatively and on postoperative days 3 and 5
|
|
Fecal Short-Chain Fatty Acid (SCFA) Levels
Časové okno: Preoperatively and on postoperative days 3 and 5
|
Fecal concentrations of short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, will be measured to assess gut microbial metabolic activity. Changes in individual SCFA concentrations before and after surgery will be compared among the three treatment groups. |
Preoperatively and on postoperative days 3 and 5
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Patologické procesy
- Novotvary podle místa
- Novotvary
- Střevní nemoci
- Gastrointestinální novotvary
- Novotvary trávicího systému
- Nemoci trávicího systému
- Gastrointestinální onemocnění
- Kolorektální novotvary
- Střevní novotvary
- Rektální onemocnění
- Patologické stavy, příznaky a symptomy
- Rektální novotvary
- Pooperační komplikace
Další identifikační čísla studie
- K10393
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Individual participant data will not be shared with other researchers due to participant privacy and confidentiality considerations and the absence of an approved data-sharing plan.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .